Impel Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
Impel Pharmaceuticals (NASDAQ: IMPL) is set to present at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 5:00 p.m. ET in Miami. CEO Adrian Adams will provide a company overview, highlighting Impel's focus on transformative therapies for central nervous system diseases. The event will feature a live webcast accessible through their Investor section. Impel is known for its Trudhesa® nasal spray for migraine treatment and is developing INP105 for agitation in autism patients.
- None.
- None.
SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that Adrian Adams, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 5:00 p.m. ET in Miami, Florida.
A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelpharma.com/. A replay of the presentation will be available on the website for 90 days.
About Impel Pharmaceuticals Inc.
Impel Pharmaceuticals is a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. Impel offers and is developing treatments that pair its proprietary POD® technology with well-established therapeutics. In addition to Trudhesa® nasal spray, which is approved in the United States for the acute treatment of migraine with or without aura in adults, Impel is also developing INP105 for the acute treatment of agitation and aggression in patients with autism.
For additional information about Impel, please visit www.ImpelPharma.com
Contact:
Media Relations:
Melyssa Weible
Elixir Health Public Relations
Phone: (1) 201-723-5805
Email: mweible@elixirhealthpr.com
Investor Relations
Christina Tartaglia
Stern Investor Relations
Phone: 212-362-1200
Email: christina.tartaglia@sternir.com
FAQ
When will Impel Pharmaceuticals present at the H.C. Wainwright Global Investment Conference?
Who is presenting on behalf of Impel Pharmaceuticals at the conference?
What is the focus of Impel Pharmaceuticals' therapies?
How can I access the live webcast of Impel Pharmaceuticals' presentation?
What is Trudhesa® and its purpose?
